Nurix Therapeutics Inc.

At $26.80, Nurix Therapeutics' price is 225% above the $8.25 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 11.65 times earnings and 7.92 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

Intrinsiqq's calculator puts Nurix Therapeutics' fair value at $8.25 a share. It grows earnings per share 5% a year for 5 years, applies an exit P/E of 5.3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $6.18. Every input can be changed on the Intrinsic Value tab.

Nurix Therapeutics scores 83 out of 100 on Intrinsiqq's quality score, which makes it a high-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is revenue growth at 106.5%, and its weakest is share count change at 139.0%. The Quality tab shows every check against its target.

No. Nurix Therapeutics (NRIX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.